- Pharmaceutical companies, including UK-based AstraZeneca and GSK, are awaiting the impact of impending US tariffs proposed by President Donald Trump.
- The tariffs, expected to be similar to the 25 per cent tariffs imposed on auto parts, aim to boost drug production within the United States.
- While UK drug prices and NHS supply are unlikely to be immediately affected, long-term impacts on availability and research and development are possible.
- GSK, with over 50 per cent of its sales in the US, is optimistic about adapting but has acknowledged the uncertainty surrounding the tariffs.
- Pharmaceutical company share prices have already declined in anticipation of the tariffs, creating uncertainty in the sector.
IN FULL
